Release Date: August 15, 2025

Expiration Date: August 15, 2026

Activity Overview

TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells. In this activity, three experts provide guidance on frequently asked questions regarding the use of ADCs in TNBC.

Target Audience

This activity is directed toward medical oncologists, advanced practice providers, nurses, pharmacists, and other health care practitioners who manage patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Develop evidence-based strategies for integrating ADCs in the management of patients with metastatic TNBC
Apply effective methods to mitigate adverse effects associated with ADCs in patients with metastatic TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

GET STARTED WITH THIS PROGRAM:

Related Content